OUR MISSION: To develop targeted cancer therapeutics that provide better outcomes for patients.
We’re building an Australian company with an ambitious vision to revolutionise cancer treatment across the globe. With exceptional expertise in drug discovery and pre-clinical development, a pipeline of promising drug candidates, and a team comprised of experienced executives, Aucentra is poised for success.
All of our compounds are designed to be first-in-class or best-in-class anticancer agents. Our next step is to expand our clinical activities to take our discoveries into Phase II clinical trials.
Investment sought: A$5M - A$20M
- Australian privately owned biotechnology company with 7 new, patented drug candidates in development.
- Targeted therapies for a range of cancers including glioblastoma, colorectal cancer, prostate cancer and ovarian cancer ready to proceed to clinical trials in Australia within 12 months.
- Global market opportunity exceeding $30 billion and the opportunity to invest early in a rapidly growing Australian biotech.
- Aucentra Therapeutics
Expected start date
December 01, 2020
Expected end date
December 01, 2023
Funding round finish date